STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRS
  4. [ARS] Kalaris Therapeutics, Inc. SEC Filing

[ARS] Kalaris Therapeutics, Inc. SEC Filing

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - Kalaris Therapeutics, Inc.

ARS Filing - Kalaris Therapeutics, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Kalaris Therapeutics, Inc. (KLRS)

Acceptance Date: 2025-07-01T07:40:26.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Stock KLRS logo
Kalaris Therapeutics Inc

NASDAQ:KLRS

KLRS Rankings

#5331 Ranked by Market Cap
N/A Ranked by Dividends

KLRS Latest News

Aug 13, 2025
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Jun 2, 2025
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
May 23, 2025
Kalaris to Participate at Stifel Ophthalmology Forum
May 14, 2025
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Apr 4, 2025
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

KLRS Latest SEC Filings

Aug 13, 2025
[10-Q] Kalaris Therapeutics, Inc. Quarterly Earnings Report
Aug 13, 2025
[8-K] Kalaris Therapeutics, Inc. Reports Material Event
Aug 13, 2025
[8-K] Kalaris Therapeutics, Inc. Reports Material Event
Jul 29, 2025
[SCHEDULE 13G/A] Kalaris Therapeutics, Inc. SEC Filing
Jul 1, 2025
[DEFA14A] Kalaris Therapeutics, Inc. Additional Proxy Soliciting Materials

KLRS Stock Data

42.64M
15.27M
18.34%
70.33%
0.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PALO ALTO